
Insulet (PODD) Stock Forecast & Price Target
Insulet (PODD) Analyst Ratings
Bulls say
Insulet demonstrated strong financial performance with global Omnipod sales increasing by 26% year-over-year on an underlying basis in Q4'24, reaching $586 million. The company achieved a significant milestone with over 500,000 active customers and posted overall 2024 sales of $2.07 billion, reflecting a 22% growth year-over-year, alongside earnings per share of $3.24, surpassing consensus estimates. The favorable market dynamics, including stable customer retention rates and continuous adoption of the Omnipod system, underscore Insulet's competitive position and potential for sustained growth in the diabetes management sector.
Bears say
Insulet's operating margins have declined year-over-year, with a decrease of 240 basis points, signaling potential challenges in managing operational efficiency, while its Adjusted EBITDA margin also deteriorated by 160 basis points. The company's guidance for 2025 indicates slower sales growth for its Drug Delivery segment, with anticipated revenue declines of 45-55% year-over-year, which may overshadow the projected growth of the Omnipod system. Furthermore, Insulet's reliance on third-party distributors raises concerns about market access and sales performance, particularly if competitors introduce more effective diabetes treatment options, jeopardizing the company's revenue stability.
This aggregate rating is based on analysts' research of Insulet and is not a guaranteed prediction by Public.com or investment advice.
Insulet (PODD) Analyst Forecast & Price Prediction
Start investing in Insulet (PODD)
Order type
Buy in
Order amount
Est. shares
0 shares